NovMetaPharma Co., Ltd. (XKON:229500)

Market Cap	136.63B +125.8%
Revenue (ttm)	1.30B +21.4%
Net Income	408.03M
EPS	120.00
Shares Out	12.71M
PE Ratio	89.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,732
Average Volume	4,070
Open	11,680
Previous Close	n/a
Day's Range	11,050 - 11,680
52-Week Range	4,810 - 17,890
Beta	0.28
RSI	33.39
Earnings Date	n/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic and fibrotic diseases in South Korea. It is developing Cyclo-Z, which is in phase 2 clinical stage; and CHP that is in phase 1 clinical stage for the treatment of diabetic kidney disease, obesity, and rare conditions, including FSHD and DMD. The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015. NovMetaPharma Co., Ltd. was incorporated in 2010 and is headquartered in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 229500